Aviad E. Raz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aviad E. Raz has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Silke Schicktanz
Institut für Ethik und Geschichte der Medizin, Universitätsmedizin Göttingen, Göttingen, Deutschland
19 shared publications - Christoph Rehmann-Sutter
Universität zu Lübeck
8 shared publications - Tamar Nov-Klaiman
University of Augsburg
8 shared publications - Yael Hashiloni-Dolev
Faculty of Humanities and Social Sciences Department of Sociology and Anthropology Ben‐Gurion University of the Negev Beer‐Sheva Israel
8 shared publications Stefan Timmermans
Department of Sociology, UCLA, Los Angeles, CA
6 shared publicationsMarcela Atar
5 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (17) , 4940-4944
Reimagining reproductive futures
- 5 August 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (17) , 4940-4944
Open AccessReimagining reproductive futures
- Open Access
- 10 December 2025
- Published by Springer Nature in EMBO Reports
- Vol. 27 (2) , 265-268
The new frontier in assisted reproduction
AI-assisted polygenic embryo screening is a new technology to predict embryonic implantation, disease risk and non-clinical traits for IVF embryos. To highlight its social and ethical implications, we locate it within the national landscapes of Germany’s legal caution, Israel’s techno-enthusiasm and US market liberalism.
- 10 December 2025
- Published by Springer Nature in EMBO Reports
- Vol. 27 (2) , 265-268
Open AccessThe new frontier in assisted reproduction
AI-assisted polygenic embryo screening is a new technology to predict embryonic implantation, disease risk and non-clinical traits for IVF embryos. To highlight its social and ethical implications, we locate it within the national landscapes of Germany’s legal caution, Israel’s techno-enthusiasm and US market liberalism.
- Open Access
- 10 November 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e74038
Use First, Trust Later? Exploring How Health Care Providers View the Gaps Between AI’s Regulation and Its Implementation
The regulatory focus on premarket approval, overlooking and limiting the life cycle, real-world adaptiveness potential of artificial intelligence in health care, requires ongoing oversight and quality assurance by health care providers–cum-deployers, especially during early adoption.
- 10 November 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e74038
Open AccessUse First, Trust Later? Exploring How Health Care Providers View the Gaps Between AI’s Regulation and Its Implementation
The regulatory focus on premarket approval, overlooking and limiting the life cycle, real-world adaptiveness potential of artificial intelligence in health care, requires ongoing oversight and quality assurance by health care providers–cum-deployers, especially during early adoption.
- Open Access
- 27 September 2025
- Published by Elsevier in SSM - Qualitative Research in Health
- Vol. 8
“Sailing the ship while building it”: Sandbox regulation and the political economy of Israeli healthcare AI innovation
- 27 September 2025
- Published by Elsevier in SSM - Qualitative Research in Health
- Vol. 8
Open Access“Sailing the ship while building it”: Sandbox regulation and the political economy of Israeli healthcare AI innovation
- Open Access
- 27 September 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (11) , 3713-3721
Should recipient parents have access to gamete donors’ raw genomic data? Clinical, legal, and ethical considerations
Background: Genomic sequencing yields vast amounts of data, and the access of patients and research participants to their raw genomic data raises ethical and practical dilemmas. Purpose: This paper aims to examine a challenging, underexplored question: whether gamete donors' raw data should be provided to recipient parents. Methods: Using a clinical case, we explore the key ethical, legal, and clinical implications of such access, weighing the advantages, disadvantages, and potential alternatives. Results: Ethical implications include the feasibility of meaningful informed consent from donors for complex genetic testing, sometimes years after donation; privacy considerations; the type of medical information recipients can or should hold on donors; potential conflicts of interest between the donor and the child; and the potential for raised costs and commercial interests. Clinical implications involve the implementation of systems of storing donors' raw data and devices of re-contacting past donors. Legal aspects include the informed consent of gametes donors to disclose their raw data to recipient parents and privacy protections, including their right to keep their raw data in confidence. Conclusion: We advocate a cautious approach that favors clinically mediated access over unrestricted parental access.
- 27 September 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (11) , 3713-3721
Open AccessShould recipient parents have access to gamete donors’ raw genomic data? Clinical, legal, and ethical considerations
Background: Genomic sequencing yields vast amounts of data, and the access of patients and research participants to their raw genomic data raises ethical and practical dilemmas. Purpose: This paper aims to examine a challenging, underexplored question: whether gamete donors' raw data should be provided to recipient parents. Methods: Using a clinical case, we explore the key ethical, legal, and clinical implications of such access, weighing the advantages, disadvantages, and potential alternatives. Results: Ethical implications include the feasibility of meaningful informed consent from donors for complex genetic testing, sometimes years after donation; privacy considerations; the type of medical information recipients can or should hold on donors; potential conflicts of interest between the donor and the child; and the potential for raised costs and commercial interests. Clinical implications involve the implementation of systems of storing donors' raw data and devices of re-contacting past donors. Legal aspects include the informed consent of gametes donors to disclose their raw data to recipient parents and privacy protections, including their right to keep their raw data in confidence. Conclusion: We advocate a cautious approach that favors clinically mediated access over unrestricted parental access.
- Open Access
- 26 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1651934
Who moved my scan? Early adopter experiences with pre- and post-market healthcare AI regulation challenges
Real-world clinical experience provides a much-needed opportunity for deep learning AI algorithms to evolve and improve. Yet, it also constitutes a regulatory challenge, since such potential for learning may essentially change the algorithm and introduce new biases. We focus on the gaps between “lifecycle” regulation and implementation from the perspective of the deployers, addressing three interconnected dimensions: (a) How precautionary regulation affects AI deployment in healthcare, (b) How healthcare providers view explainable AI (XAI), and (c) How AI deployment influences, and is influenced by, team routines in clinical settings. We conclude by suggesting ways in which the ends of healthcare AI regulation and deployment can successfully meet.
- 26 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1651934
Open AccessWho moved my scan? Early adopter experiences with pre- and post-market healthcare AI regulation challenges
Real-world clinical experience provides a much-needed opportunity for deep learning AI algorithms to evolve and improve. Yet, it also constitutes a regulatory challenge, since such potential for learning may essentially change the algorithm and introduce new biases. We focus on the gaps between “lifecycle” regulation and implementation from the perspective of the deployers, addressing three interconnected dimensions: (a) How precautionary regulation affects AI deployment in healthcare, (b) How healthcare providers view explainable AI (XAI), and (c) How AI deployment influences, and is influenced by, team routines in clinical settings. We conclude by suggesting ways in which the ends of healthcare AI regulation and deployment can successfully meet.
- Open Access
- 12 July 2025
- Published by Springer Nature in Social Theory & Health
- Vol. 23 (1) , 1-20
“It has to somehow permeate to the public”: expert views on the solidaristic potential of Israel’s National genomic biobank initiative
The 2018 Digital Health Initiative (DHI) implemented by Israel included the establishment of a national biobank. Establishing a national biobank was clouded in ample rhetoric of solidarity promising scientific and economic progress, and financial benefits. To assess the potential of these promises, we conducted 15 semi-structured interviews with experts with a management, health or political background from Israel over a one-year period. Applying a data solidarity framework to the insights gained from the interviews, we concluded that a national biobank indeed offers great potential for medical progress under the condition that data use is transparent and mechanisms for access are clear. In contrast, we estimate that claims on economic and financial benefits are less certain and depend on controversial ideas like the trickle-down effect. To strengthen the beneficial effects of a national biobank, we recommend policymakers adhere to data solidarity to avoid misappropriating solidarity.
- 12 July 2025
- Published by Springer Nature in Social Theory & Health
- Vol. 23 (1) , 1-20
Open Access“It has to somehow permeate to the public”: expert views on the solidaristic potential of Israel’s National genomic biobank initiative
The 2018 Digital Health Initiative (DHI) implemented by Israel included the establishment of a national biobank. Establishing a national biobank was clouded in ample rhetoric of solidarity promising scientific and economic progress, and financial benefits. To assess the potential of these promises, we conducted 15 semi-structured interviews with experts with a management, health or political background from Israel over a one-year period. Applying a data solidarity framework to the insights gained from the interviews, we concluded that a national biobank indeed offers great potential for medical progress under the condition that data use is transparent and mechanisms for access are clear. In contrast, we estimate that claims on economic and financial benefits are less certain and depend on controversial ideas like the trickle-down effect. To strengthen the beneficial effects of a national biobank, we recommend policymakers adhere to data solidarity to avoid misappropriating solidarity.
- Open Access
- 25 April 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (12) , 1555-1557
More of the same? Israel’s expanded carrier screening for cystic fibrosis
- 25 April 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (12) , 1555-1557
Open AccessMore of the same? Israel’s expanded carrier screening for cystic fibrosis
- Open Access
- 14 August 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (2) , 154-155
Negotiating ‘severity’ in plain sight
- 14 August 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (2) , 154-155
Open AccessNegotiating ‘severity’ in plain sight